All samples·Sample analysis
Get your own pass — $199
granted.bioAll samples
Analysis

radioligand therapy for prostate cancer

Overview
  • Dashboard
Analysis
  • What Surprised Us
  • Field Maturity
  • Funding Landscape
  • Competitive Topology
  • White Space
  • Market Context
Data
  • Projects115
  • Clinical Trials500
  • Patents29
  • Publications646
  • Organizations52
  • Researchers125
Reference
  • Methodology
Back
radioligand therapy for prostate cancerOrganizationsPDX PHARMACEUTICALS, INC.

PDX PHARMACEUTICALS, INC.

Projects attributed to PDX PHARMACEUTICALS, INC. within this analysis sample.

In This Analysis
Projects
1
NIH Funding
$2.2M
Projects(1)
ProjectPICategoryFunding
PLK1 and EGFR targeted nanoconstruct as a monotherapy and a radiation sensitizer for lung cancer
5R44CA285233-03
NGAMCHERDTRAKUL, WORAPOLBiotools$2.2M
See PDX PHARMACEUTICALS, INC.’s full platform profile
Cross-source view across the entire granted.bio dataset — projects, trials, patents, and publications spanning every topic, not just this analysis.